ACTRN12618001955202终止1 期
A Phase 1a/1b Safety and Tolerability Study of FPT155 in Patients with Advanced Solid Tumors.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. 18 years of age or older
- •2. Solid tumors (except primary CNS tumors)
- •3. For patients in Phase 1a dose escalation and Phase 1a dose exploration only: Disease that is unresectable, locally advanced, or metastatic and has progressed following all standard treatments or is not appropriate for standard treatments
- •4. All patients must have at least one measurable lesion at baseline
- •5. In good functional status (daily activity, physical ability)
- •6. Blood lab values within protocol specified limits
- •Only Key inclusion criteria is listed.
排除标准
- •1. No significant medical condition (e.g. cardiac, infectious)
- •2. Active, known, or suspected autoimmune disease.
- •3. Untreated or active central nervous system (CNS) metastases.
- •Only Key exclusion criteria is listed.
研究者
相似试验
撤回
1 期
Safety and tolerability of the Traditional Chinese Medicine Formulation GOPAC in patients with advanced malignancyAdvanced malignancy (palliative)Cancer - Other cancer typesACTRN12609000652279Sydney South West Area Health Service70
进行中（未招募）
不适用
PHASE 1 SAFETY AND TOLERABILITY STUDY OF FIGITUMUMAB COMBINED WITH PEGVISOMANT IN PATIENTS WITH ADVANCED SOLID TUMORSAdvanced Solid TumorsMedDRA version: 9.1Level: LLTClassification code 10049280Term: Solid tumourEUCTR2009-012769-74-FIPfizer Inc., 235 East 42nd Street, New York, NY 11001746
进行中（未招募）
不适用
PHASE 1 SAFETY AND TOLERABILITY STUDY OF FIGITUMUMAB COMBINED WITH PEGVISOMANT IN PATIENTS WITH ADVANCED SOLID TUMORSAdvanced Solid TumorsMedDRA version: 9.1Level: LLTClassification code 10049280Term: Solid tumourEUCTR2009-012769-74-DEPfizer Inc., 235 East 42nd Street, New York, NY 11001746
进行中（未招募）
1 期
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113EUCTR2011-005718-12-ESARIAD Pharmaceuticals, Inc.137
进行中（未招募）
1 期
Relatlimab + Nivolumab in Pediatric and Young Adult Lymphomas(RELATIVITY-069)CTIS2023-503715-14-00Bristol Myers Squibb International Corporation99